Announcement
GENERAL: PEB: United Healthcare Issues Positive Coverage Cxbladder
10:36am
PEB
09/04/2021 10:36
GENERAL
PRICE SENSITIVE
REL: 1036 HRS Pacific Edge Limited
GENERAL: PEB: United Healthcare Issues Positive Coverage Cxbladder
UNITED HEALTHCARE ISSUES POSITIVE COVERAGE DECISION FOR CXBLADDER
US' largest healthcare insurer publishes coverage of Cxbladder tests
Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to
advise that its Cxbladder bladder cancer diagnostic tests are now covered by
United Healthcare, the largest healthcare group in the US.
Effective from 1 April 2021, Cxbladder is now being covered as a 'medically
necessary bladder tumor marker test', under United Healthcare's Molecular
Pathology/Molecular Diagnostics/Genetic Testing (Medicare Advantage) -
Medical Policy.
United Healthcare has over 50 million members with more than 5.7 million
Medicare Advantage members. In 2019, UnitedHealth Group had a 14.1 percent
share of the U.S. health insurance market, with direct premiums written
amounting to approximately US$107 billion . The organisation partners with
6,500 hospitals and care facilities nationwide, and more than 1.3 million
physicians and other providers.
Including the positive coverage decision issued by the Centres for Medicare
and Medicaid Services (CMS) in 2020, more than 110 million Americans now have
coverage of Cxbladder non-invasive, highly accurate tests for the detection
and management of urothelial and bladder cancer.
Pacific Edge CEO David Darling states: "Gaining coverage with the US' largest
insurer is a significant achievement for Pacific Edge and will be of benefit
to millions of Americans seeking better clinical solutions and health
outcomes for bladder cancer diagnosis.
"This positive coverage decision reflects the validation that comes from
independent published clinical evidence, inclusion in guidelines and coverage
with other providers such as the CMS. It adds further validation of
Cxbladder and a point of inflexion for other healthcare insurers."
Jackie Walker, the CEO of PEDUSA, Pacific Edge's US business, said: "Over the
last six months, we have been expanding our US sales team to deliver on the
growth opportunities available to Cxbladder. These specialist sales people
will now be working closely with urologists associated with United Healthcare
to encourage and support them in their use of our Cxbladder products."
ENDS
For more information contact:
David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800
For media assistance, please contact: Jackie Ellis on +64 27 246 2505 or
email jackie@ellisandco.co.nz
OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and management of
cancer. Its Cxbladder suite of non-invasive, simple to use and accurate
diagnostic tests provide actionable results, and better detection and
management of urothelial cancer. The company is developing and
commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The
company's products have been tested and validated in international
multi-centre clinical studies.
ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional
phenotypic and clinical risk factors to accurately identify patients with
haematuria who have a low probability of bladder cancer and may not require a
more extensive urological evaluation. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and
invasive work-up in patients who have a low probability of having urothelial
carcinoma.
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients' urine. Cxbladder
Detect provides clinicians with a quick, cost effective and accurate measure
of the presence of the cancer as an effective adjunct to cystoscopy.
ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for
recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and
requires life-long surveillance. Cxbladder Monitor accurately identifies
patients with a prior history of urothelial cancer (UC) whose Cxbladder
Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct
test to cystoscopy in the management of patients for ongoing evaluation of
recurrent bladder cancer.
ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive
or more advanced bladder cancer. Cxbladder Resolve, when used as part of the
primary evaluation of haematuria and/or in conjunction with other Cxbladder
tests (Triage, Detect), is designed to assist clinicians by accurately
identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may
be warranted, or who can be prioritised for further investigation in high
throughput settings.
Refer to www.cxbladder.com for more information.
End CA:00370436 For:PEB Type:GENERAL Time:2021-04-09 10:36:55
Click here
to view related attachments.
